Literature DB >> 15655509

Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes.

Richard J Wilson1, Heather Giles.   

Abstract

Prostaglandin E(2) produced endothelium-independent relaxation of phenylephrine- and 5-HT-contracted piglet saphenous vein (PSV; pEC(50)=8.6+/-0.2; n=6). The prostanoid EP(4) receptor antagonist GW627368X (30-300 nM) produced parallel rightward displacement of PGE(2) concentration-effect (E/[A]) curves (pK(b)=9.2+/-0.2; slope=1). Higher concentrations of GW627368X did not produce further rightward shifts, revealing the presence of non-EP(4) prostanoid receptors. In all, 18 other prostanoid receptor agonists relaxed PSV in a concentration-related manner. Relative potencies of agonists most sensitive to 10 muM GW627368X (and therefore predominantly activating EP(4) receptors) correlated well with those at human recombinant EP(4) receptors in human embryonic kidney (HEK-293) cells (r(2)=0.74). In the presence of 10 microM GW627368X, the rank order of agonist relative potency matched that of the human recombinant EP(2) receptor in Chinese hamster ovary cells (r(2)=0.72). Iloprost, cicaprost and PGI(2) relaxed PSV maximally and were antagonised by 10 microM GW627368X, demonstrating that they were full EP(4) receptor agonists. Residual responses to these compounds in the presence of GW627368X suggested the presence of IP receptors.BW245C relaxed PSV maximally (pEC(50)=6.8+/-0.1). In the presence of 10 microM GW627368X, BW245C produced biphasic E/[A] curves (phase one pEC(50)=6.6; alpha=24%; phase two pEC(50)=5.1; alpha=112%). Phase two was antagonised by the DP receptor antagonist BW A868C (1 microM), demonstrating that BW245C is an agonist at DP and EP4 receptors. We conclude that PSV contains EP(4), EP(2), DP and IP receptors; IP receptor agonists are also porcine EP(4) receptor agonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655509      PMCID: PMC1576018          DOI: 10.1038/sj.bjp.0706088

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.

Authors:  M Abramovitz; M Adam; Y Boie; M Carrière; D Denis; C Godbout; S Lamontagne; C Rochette; N Sawyer; N M Tremblay; M Belley; M Gallant; C Dufresne; Y Gareau; R Ruel; H Juteau; M Labelle; N Ouimet; K M Metters
Journal:  Biochim Biophys Acta       Date:  2000-01-17

Review 2.  Drug efficacy at G protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

Review 3.  Prostanoid receptors: structures, properties, and functions.

Authors:  S Narumiya; Y Sugimoto; F Ushikubi
Journal:  Physiol Rev       Date:  1999-10       Impact factor: 37.312

Review 4.  PGI2-receptors and molecular mechanisms in platelets and vasculature: state of the art.

Authors:  D Oliva; S Nicosia
Journal:  Pharmacol Res Commun       Date:  1987-11

Review 5.  The biology and pharmacology of PGD2.

Authors:  H Giles; P Leff
Journal:  Prostaglandins       Date:  1988-02

6.  Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins.

Authors:  L Walch; V de Montpreville; C Brink; X Norel
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

7.  Functional pharmacology of human prostanoid EP2 and EP4 receptors.

Authors:  Richard J Wilson; Sharron A Rhodes; Richard L Wood; Vanessa J Shield; L Staton Noel; David W Gray; Heather Giles
Journal:  Eur J Pharmacol       Date:  2004-10-06       Impact factor: 4.432

Review 8.  Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.

Authors:  J B Smith; H Araki; A M Lefer
Journal:  Circulation       Date:  1980-12       Impact factor: 29.690

9.  Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor.

Authors:  Rung-chi Li; Tereza Cindrova-Davies; Jeremy N Skepper; Lynda A Sellers
Journal:  Circ Res       Date:  2004-02-12       Impact factor: 17.367

10.  Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue.

Authors:  B J Whittle; S Moncada; K Mullane; J R Vane
Journal:  Prostaglandins       Date:  1983-02
View more
  8 in total

1.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

2.  GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.

Authors:  Richard J Wilson; Gerard M P Giblin; Susan Roomans; Sharron A Rhodes; Kerri-Ann Cartwright; Vanessa J Shield; Jason Brown; Alan Wise; Jannatara Chowdhury; Sara Pritchard; Jim Coote; Lloyd S Noel; Terry Kenakin; Cynthia L Burns-Kurtis; Valerie Morrison; David W Gray; Heather Giles
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

3.  Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure.

Authors:  Martin Leduc; Xin Hou; David Hamel; Melanie Sanchez; Christiane Quiniou; Jean-Claude Honoré; Olivier Roy; Ankush Madaan; William Lubell; Daya R Varma; Joseph Mancini; François Duhamel; Krishna G Peri; Vincent Pichette; Nikolaus Heveker; Sylvain Chemtob
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

4.  Characterization of biosynthesis and modes of action of prostaglandin E2 and prostacyclin in guinea pig mesenteric lymphatic vessels.

Authors:  Sonia Rehal; Pauline Blanckaert; Simon Roizes; Pierre-Yves von der Weid
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

5.  Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.

Authors:  E Herradón; M I Martín; V López-Miranda
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

6.  Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo.

Authors:  Ines M Macias-Perez; Roy Zent; Monica Carmosino; Matthew D Breyer; Richard M Breyer; Ambra Pozzi
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

7.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

8.  Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype.

Authors:  N Foudi; L Kotelevets; L Louedec; G Leséche; D Henin; E Chastre; X Norel
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.